Stockreport

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Cybin Inc. Common Shares  (CYBN) 
PDF - Successfully completed enrollment of 36 participants in Phase 2 study of CYB004, the Company’s deuterated dimethyltryptamine (“DMT”) program for the treatment of Gener [Read more]